Related Experiment Video
Updated: Aug 5, 2026

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition
Published on: August 20, 2016
New Drugs on the Horizon: Matrix Metalloproteinase Inhibitors
1Vanderbilt University Medical Center, Division of Medical Oncology, Department of Medicine, Nashville, Tennessee, 37232-5536, USA. mace.rothenberg@mcmail.vanderbilt.edu
Abstract:
Matrix metalloproteinases (MMPs) are a family of enzymes involved in a number of normal cellular processes, such as regulation of endometrial growth and menstruation, and abnormal processes, such as tumor growth, invasion, and metastasis. There are now 18 distinct enzymes that fall into three functional classifications based on their substrate target: collagenases which degrade fibrillar collagen; gelatinases which degrade denatured and basement membrane collagens, and stromelysins which degrade proteoglycans and glycoproteins. The MMPs can also be separated into five categories based on structural and functional similarities.
More Related Videos
Related Concept Videos
Drugs that Stabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules
Role of Matrix Metalloproteases in Degradation of ECM
A...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
FDA Approved Drugs: Changes to Approved Drugs

